Vor Biopharma Inc. (VOR) Dividend History

Vor Biopharma Inc. (VOR) is a biotechnology company focused on developing targeted therapies for cancer using cell engineering technologies. The company aims to create treatments that selectively eliminate cancer cells while preserving healthy cells, leveraging its proprietary gene-editing platforms. Founded to address challenges in oncology, Vor Biopharma emphasizes precision medicine approaches to improve patient outcomes.

100 Cambridgepark Drive, Cambridge, MA, 02140
Phone: 617-655-6580
Website:

Dividend History

Vor Biopharma Inc. currently does not pay dividends

Company News

  • Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors

    Vor Bio, a clinical-stage cell and genome engineering company, has appointed Erez Kalir, a life sciences and technology investor and entrepreneur, to its Board of Directors. Kalir's extensive experience in the biotech sector and track record of fostering innovation will be valuable as Vor Bio continues to execute its strategic vision.

    GlobeNewswire Inc.
  • Vor Bio Announces $55.6 Million Private Placement

    Vor Bio, a clinical-stage cell and genome engineering company, announced a $55.6 million private financing that will fund its pipeline development and extend its cash runway through 2025. The company plans to announce updated clinical data from its VBP301 and VBP101 trials in 2025.

    GlobeNewswire Inc.
  • Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer

    Vor Bio, a clinical-stage cell and genome engineering company, has appointed Han Choi, M.D., LL.M., as its new Chief Financial Officer. Dr. Choi brings over 25 years of experience in investment management, business development, and corporate strategy in the pharmaceutical and biotechnology industry.

    GlobeNewswire Inc.
  • Gene Editing Therapeutics Market Forecast 2024-2029: A $1 Billion Market by 2029, with a Forecasted CAGR of 147%

    The gene editing therapeutics market is expected to grow significantly, reaching $1 billion by 2029 with a CAGR of 147%. Key drivers include the increasing prevalence of chronic and rare genetic diseases, as well as the need for precision medicine.

    GlobeNewswire Inc.
    Featured Companies: ALLO BEAM CRBU CRSP DTIL EDIT NTLA SGMO VRTX
  • Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., June 04, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of June 1, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 1,000 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 1,500 shares of Vor Bio’s common stock to one newly hired employee. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

    GlobeNewswire Inc.
Dividend data last updated 06/07/2025 00:34:09 UTC